MedTrace Logo

Trimethoprim/Sulfamethoxazole Combined With Caspofungin as First-line Therapy in PCP

NCT03978559 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2019-09-12

No results posted yet for this study

Summary

This is a prospective, randomized clinical trial. During the study, non-HIV patients who are admitted to ICU due to Pneumocystic pneumonia (PCP) and have not received anti-PCP therapy or have received therapy less than 48hrs will be randomized (1:1) to received caspofungin combined with trimethoprim-sulfamethoxazole or trimethoprim-sulfamethoxazole alone.

The aim of this study is to compare the effectiveness of caspofungin combined with trimethoprim-sulfamethoxazole with that of conventional therapy (trimethoprim-sulfamethoxazole alone) as first-line therapy in the treatment of severe Pneumocystis pneumonia (PCP) in non-HIV patients.

Conditions

  • Pneumocystis Pneumonia

Interventions

DRUG

caspofungin

caspofungin 70mg ivdrip the first day, then 50mg ivdrip qd for 21days

DRUG

TMP/SMZ(trimethoprim/sulfisoxazole)

TMP:15mg/kg/d for 21 days +SMZ:75mg/kg/d for 21days

DRUG

Methylprednisolone

40mg ivdrip q12h for 5 days , then 40mg ivdrip qd for 5 days , 20mg for 11 days

Sponsors & Collaborators

  • Bin Du

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-08-14
Primary Completion
2022-06-20
Completion
2022-07-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03978559 on ClinicalTrials.gov